Insights

BARD1 (ASX:BD1) share price falls 6% on placement update

The medical diagnostics company has secured the first part of its equity raise…
The post BARD1 (ASX:BD1) share price falls 6% on placement update appeared first on The Motley Fool Australia. –

The BARD1 Life Sciences Ltd (ASX: BD1) share price is deep in negative territory late this afternoon. This comes after the medical diagnostics company provided investors with an update on its capital raising efforts.

At the time of writing, BARD1 shares are down 6.39% to $1.685.

What’s happening to the BARD1 share price?

BARD1 shares are falling despite a successful capital raise to accelerate the development and commercialisation of its cancer diagnostics pipeline.

According to its release, the company has raised $15 million (before costs) through a placement. The offer saw sophisticated, institutional and professional investors apply for the shares. The company said this shows strong support for the programs, which are focused on the early detection of cancer to improve patient outcomes.

Around 9.67 million new ordinary shares will be added to its registry at a price of $1.55 cents a pop. This represents a discount of 13.9% to the last closing price of $1.80 per share on 20 July 2021.

In addition, BARD1 noted that for every 2 shares issued under the placement, each investor will be entitled to one free quoted option. This will be exercisable at a price of $2.32 until the expiry date of 24 August 2023.

The shares will be ranked equally and BARD1 will use its existing placement capacity to create the new shares. Under listing rule 7.1 and 7.1A, this allows the allotted shares to be issued without shareholder approval.

The proceeds of the placement will primarily be used to advance SubB2M programs for breast and ovarian cancers. These programs have so far shown high accuracy in proof-of-concept studies. BARD1 is aiming to have a laboratory partner in the United States in 2023.

Settlement of the new shares is expected to occur on 23 August 2021.

Furthermore, the company is seeking to raise another $2 million through a Share Purchase Plan (SPP). The SPP will offer the same terms as the placement.

Post completion of both capital raising components, BARD1 forecasts a proforma net cash balance of around $20.6 million.

Management commentary

BARD1 CEO Dr Leearne Hinch touched on the company’s plans, saying:

BARD1 is developing a pipeline of cancer diagnostics for the early detection of breast, ovarian, prostate and pancreatic cancers. We are advancing our cancer diagnostics pipeline towards commercialisation, with a focus on our lead SubB2M programs for breast and ovarian cancers that have shown high accuracy in proof-of-concept studies. The funds raised will accelerate development, validation and planned commercial launch of these products as laboratory developed tests in the US with a laboratory partner in 2023.

The BARD1 share price has gained 80% in the last 12 months, and is up more than 140% in 2021.

The post BARD1 (ASX:BD1) share price falls 6% on placement update appeared first on The Motley Fool Australia.

Should you invest $1,000 in BARD1 right now?

Before you consider BARD1, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and BARD1 wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Here’s why the BARD1 (ASX:BD1) share price is frozen today
Why the BARD1 (ASX:BD1) share price is surging 10% higher

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!